TransCode Therapeutics, Inc. RNAZ
Set alert
At close · Oct 30
After hours · Oct 30, 6:35 PM ET
- YTD
- -76.13%
- 1 year
- -85.11%
- Open
- 1.73
- Prev close
- 1.73
- Mkt cap
- 27.60M
- Vol
- 16.18K
- Avg vol
- 54.04K
- EPS
- -52.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.63
- High
- 1.79
- Forward P/E
- -5.97
- Beta
- 0.65
- Short ratio
- 0.50
- Inst. own
- 1.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 13.50
- 200-d avg
- 20.41
- 1y target
- 20.00
News
-
4 days ago benzinga.com
TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and
4 days ago prnewswire.com
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment TransCode will evaluate strategic alternatives including licensing…
6 days ago prnewswire.com
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumors BOSTON, Oct. 26,…
1 week ago prnewswire.com
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:…
2 weeks ago gurufocus.com
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
[url="]Natera, Inc.[/url] (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and [url="]TransCode Therapeutics, Inc[/url]. (Nasdaq: RNAZ),
-
2 weeks ago benzinga.com
Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based…
2 weeks ago businesswire.com
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage…
-
1 month ago benzinga.com
TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid Tumors
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumorsIn the 14 efficacy-evaluable patients:71.4% stable disease rate57.1% of…
1 month ago prnewswire.com
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors In the 14 efficacy-evaluable patients: 71.4% stable disease rate 57.1% of…
-
1 month ago benzinga.com
TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements…
1 month ago prnewswire.com
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation BOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode…
1 month ago seekingalpha.com
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript
-
1 month ago benzinga.com
TransCode Therapeutics CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its…
1 month ago prnewswire.com
TransCode Therapeutics Announces Leadership Transition
Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:…
2 months ago prnewswire.com
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate BOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD)…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…
3 months ago defenseworld.net
TransCode Therapeutics Stockholders Approve Share Issuance Plans, Board Slate
TransCode Therapeutics (NASDAQ: RNAZ) stockholders approved all proposals presented at the company's reconvened annual meeting, including several measures related to the potential issuance of common…
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's regular session. The market value of their outstanding shares is at $4.8 million. Seer (NASDAQ:SEER)…
4 months ago seekingalpha.com
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
4 months ago prnewswire.com
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
5 months ago prnewswire.com
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics.…
5 months ago feeds.benzinga.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.
5 months ago benzinga.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
5 months ago prnewswire.com
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today…
-
5 months ago benzinga.com
TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.67 percent increase over losses of $(70.16) per share from the same period last year.
-
6 months ago benzinga.com
Transcode Therapeutics Files Prospecuts For Resale Of Up To 15,955,543 Shares By Selling Stockholders
TransCode Therapeutics, Inc.15,955,543 SharesCommon StockThis prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of…
6 months ago prnewswire.com
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and…
-
6 months ago benzinga.com
TransCode Therapeutics Enters Into Agreement With Institutional Healthcare Investor For Financing Of Up To $20M
TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it…
6 months ago prnewswire.com
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and…
7 months ago defenseworld.net
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will…
7 months ago defenseworld.net
Head-To-Head Comparison: Karyopharm Therapeutics (NASDAQ:KPTI) & TransCode Therapeutics (NASDAQ:RNAZ)
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will…
-
8 months ago benzinga.com
TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
8 months ago benzinga.com
Transcode Therapeutics In Collaboration With Quantum Leap Healthcare Collaborative, Submitted An FDA Investigational New Drug Application Amendment For Planned Phase 2A Trial With Transcode's TTX-MC138
As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy…
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session